Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24378150 | 0.83 | POLB (0.47) | MAPTLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29516215 | 0.83 | POLB (0.47) | MAPTLMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24377992 | 0.81 | CYP1A2 (0.51) | MAPTLMNATHRBCYP1A2CYP3A4 | |
| SCHEMBL29516333 | 0.80 | SIRT1 (0.55) | — | |
| SCHEMBL24378022 | 0.80 | SIRT1 (0.55) | — | |
| SCHEMBL26938750 | 0.79 | SIRT3 (0.45) | — | |
| SCHEMBL16607303 | 0.73 | MAPT (0.64) | MAPTCYP1A2CYP2C9CYP2C19TSHR | |
| SCHEMBL24378145 | 0.73 | KMT2A (0.37) | MAPTTHRBALDH1A1CHRM1RAB9A | |
| SCHEMBL29516400 | 0.72 | MAPK1 (0.54) | MAPTTHRBCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL24377989 | 0.72 | MAPK1 (0.54) | MAPTTHRBCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2022087433-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | MAPT 4367/4885LMNA 1673/4885THRB 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.